Health committee  Yes, I think so. We'll go back and check, but I think that should be okay.

Health committee  I would just add that in the American example, they have just obtained new legislative authorities as well. I think these just came into effect in 2007. This also affects their tools vis-à-vis post-market authorities.

Health committee  As we move through the proposed bill and other activities, of course there is a requirement to develop regulations. Through developing regulations, we're committed to following the cabinet directive on streamlining regulation, which includes assessing costs and benefits of propos

Health committee  As you know, budget 2008 provided funding for the food and consumer safety action plan. It was about $113 million over two years. That certainly enables us to begin the work of advancing not only the life cycle approach that's outlined in the proposed legislation but also the ass

Health committee  Yes. I mean, we continue to be committed to the principle of identifying and costing activities and forming our resource allocation decisions as we move forward. I can speak to what was provided in budget 2008.

Health committee  Those decisions on how it will be allocated are still being made, so I'm not able to speak any further about that at this point.

Health committee  If I may, I believe “adverse reactions” is in fact a defined term in the regulations as they currently exist. Also, there already is a mandatory requirement on industry to submit adverse reaction reports to Health Canada. That already does exist.

Health committee  Thank you very much, Madam Chair, for the opportunity to appear in front of this committee again. We appreciate the opportunity to return to discuss the issue of post-market surveillance. I know this committee has heard from many excellent witnesses, and we're pleased to appear

Health committee  I'd say that's precisely what we're striving to do, to have a more coordinated approach to post-market surveillance activity, and as Dr. Turner was mentioning, that's a combination of increasing reporting of serious adverse drug reactions, but also doing things like working with

Health committee  The federal government has been working with provincial and territorial colleagues, as well as networks of academic centres, in developing what's been called a real world drug safety and effectiveness network, which will be used to collect data about real world impacts, tapping i